Immtech Pharmaceuticals has said that Jubo Liu has joined Immtech as Development Liaison for Clinical Trials in China. Dr. Liu will coordinate and manage Immtech's clinical development program in China, which currently includes the phase III clinical trial for pneumocystis pneumonia (PCP).
Cecilia Chan, Vice Chairman of Immtech, stated "Immtech received fast- track status from China's State Food and Drug Administration for our application to conduct the PCP Phase III trial. We are advancing into the commercialization phase and intend to significantly increase our growth opportunities in China. With his experience in drug development and in the areas of marketing and regulatory registration in China, Dr. Liu joins our team as we increase our efforts to bring products to market for the treatment of global infectious diseases."
Dr. Liu left Vertex Pharmaceuticals to join Immtech. A specialist in formulation strategies and drug discovery, he also worked as director of marketing and regulatory registration at Beijing Zhenlingxin Health Consulting in Beijing, China, and has coordinated clinical trials for both domestic and imported drugs in China.
Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases. Immtech has advanced clinical programs that include new treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections.